Pulmonary drug delivery: A review on nanocarriers for antibacterial chemotherapy

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 2945-2955

  Moreno Sastre, M ^a,b   Pastor, M ^a,b   Salomon, C J ^c,d   Esquisabel, A ^a,b   Pedraz, J L ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d Universidad Nacional de Rosario   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; MACROLIDE; NANOCARRIER; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; DRUG CARRIER; NANOPARTICLE;

AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CAUSE OF DEATH; CHEMOTHERAPY; DRUG DEGRADATION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; LUNG INFECTION; NANOENCAPSULATION; NEBULIZER; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; REVIEW; THERAPY EFFECT; WORLD HEALTH ORGANIZATION; BACTERIAL INFECTIONS; INHALATIONAL DRUG ADMINISTRATION; PROCEDURES; RESPIRATORY TRACT INFECTIONS;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG CARRIERS; DRUG THERAPY; HUMANS; NANOPARTICLES; RESPIRATORY TRACT INFECTIONS;

EID: 84949057885     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv192     Document Type: Review

References (80)

1. WHO. The Top 10 Causes of Death. Fact Sheet 310. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
2. Heijerman H, Westerman E, Conway S et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8: 295-315.
3. Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the daptomycin surveillance program (2007-2008). Diagn Microbiol Infect Dis 2009; 65: 158-62.
4. Porto JP, Santos RO, Gontijo PPF et al. Active surveillance to determine the impact of methicillin resistance on mortality in patients with bacteremia and influences of the use of antibiotics on the development of MRSA infection. Rev Soc Bras Med Trop 2013; 46: 713-8.
5. Haase R, Worlitzsch F, Schmidt F et al. Colonization and infection due to multi-resistant bacteria in neonates: a single center analysis. Klin Padiatr 2014; 226: 8-12.
6. Viswanathan R, Singh AK, Basu S et al. Multi-drug resistant Gramnegative bacilli causing early neonatal sepsis in India. Arch Dis Child Fetal Neonatal Ed 2012; 97: F182-7.
7. WHO. The Evolving Threat of Antimicrobial Resistance: Options for Actions. Geneva: WHO, 2012.
8. Gould I, Bal A. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 2013; 4: 185-91.
9. Costa H, Grenha A. Natural carriers for application in tuberculosis treatment. J Microencapsul 2013; 30: 295-306.
10. Mehanna MM, Mohyeldin SM, Elgindy NA. Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J Control Release 2014; 187: 183-97.
11. Sosnik A, Carcaboso ÁM, Glisoni RJ et al. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 2010; 62: 547-59.
12. Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine 2011; 7: 259-72.
13. Hinds WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. 2nd edn. New Jersey: John Wiley&Sons, 1999.
14. Schulz H, Muhle H. Chapter 16-respiration. In: Krinke GJ, ed. The Laboratory Rat. London: Academic Press, 2000; 323-44.
15. Newman SP, Pavia D, Garland N et al. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl 1982; 119: 57-65.
16. Heyder J, Svartengren MU. Basic principles of particle behavior in the human respiratory tract. In: Bisgaard H, O'Callaghan C, Smaldone GC, eds. Drug Delivery to the Lung. 1st edn. New York: Marcel Dekker, 2002; 21-45.
17. Patton JS. Unlocking the opportunity of tight glycaemic control. Diabetes Obes Metab 2005; 7: S5-8.
18. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002; 19: 425-98.
19. Rabanel JM, Aoun V, Elkin I et al. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. Curr Med Chem 2012; 19: 3070-102.
20. Geiser M, Kreyling WG. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol 2010; 7: 2.
21. Wong W, Crapper J, Chan HK et al. Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. J Pharm Biomed Anal 2010; 51: 853-7.
22. Nahar K, Gupta N, Gauvin R et al. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci 2013; 49: 805-18.
23. Timsina MP, Martin GP, Marriott C et al. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994; 101: 1-13.
24. Corrias F, Lai F. New methods for lipid nanoparticles preparation. Recent Pat Drug Deliv Formul 2011; 5: 201-13.
25. Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 2005; 24: 67-75.
26. Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002; 22: 129-50.
27. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 2011; 3: 1377-97.
28. Peniche H, Peniche C. Chitosan nanoparticles: a contribution to nanomedicine. Polym Int 2011; 60: 883-9.
29. Chan JM, Zhang L, Yuet KP et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009; 30: 1627-34.
30. Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012; 47: 139-51.
31. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011; 12: 62-76.
32. Akbari V, Abedi D, Pardakhty A et al. Ciprofloxacin nano-niosomes for targeting intracellular infections: an in vitro evaluation. J Nanopart Res 2013; 15: 1556.
33. Kavruk M, Celikbicak O, Ozalp V et al. Antibiotic loaded nanocapsules functionalized with aptamer gates for targeted destruction of pathogens. Chem Commun (Camb) 2015; 51: 8492-5.
34. d'Angelo I, Conte C, La Rotonda MI et al. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev 2014; 75: 92-111.
35. Andrade F, Rafael D, Videira M et al. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev 2013; 65: 1816-27.
36. Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents 2014; 43: 485-96.
37. Todoroff J, Vanbever R. Fate of nanomedicines in the lungs. Curr Opin Colloid Interface Sci 2011; 16: 246-54.
38. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 2000; 11 Suppl 2: S93-8.
39. Gainza G, Aguirre JJ, Pedraz JL et al. rhEGF-loaded PLGA-alginate microspheres enhance the healing of full-thickness excisional wounds in diabetised Wistar rats. Eur J Pharm Sci 2013; 50: 243-52.
40. Ungaro F, d'Angelo I, Coletta C et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012; 157: 149-59.
41. Beloqui A, Solinís MÁ, Gascón AR et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 2013; 166: 115-23.
42. Donaldson K, Stone V, Tran CL et al. Nanotoxicology. Occup Environ Med 2004; 61: 727-8.
43. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticlespotential implications for drug delivery. J Nanosci Nanotechnol 2004; 4: 521-31.
44. Jesús Valle MJD, González López F, Sánchez Navarro A. Pulmonary versus systemic delivery of levofloxacin: the isolated lung of the rat as experimental approach for assessing pulmonary inhalation. Pulm Pharmacol Ther 2008; 21: 298-303.
45. Bur M, Henning A, Hein S et al. Inhalative nanomedicine: opportunities and challenges. Inhal Tox 2009; 21 Suppl 1: 137-43.
46. Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 2014; 86: 7-22.
47. Bjarnsholt T, Jensen PO, Fiandaca MJ et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009; 44: 547-58.
48. Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014; 75: 81-91.
49. Healy AM, Amaro MI, Paluch KJ et al. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev 2014; 75: 32-52.
50. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392: 1-19.
51. European Council, 2014. European Pharmacopeia 8.0. Council of Europe: European Directorate for the Quality of Medicines and Healthcare, Strasbourg; 363-5.
52. Konstan MW, Flume PA, Kappler M et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011; 10: 54-61.
53. Konstan MW, Geller DE, Minic P et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011; 46: 230-8.
54. Bilton D, Serisier DJ, De Soyza A et al. Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. Eur Respiratory J 2011; 38 Suppl 55; 1925.
55. Serisier DJ, Bilton D, De Soyza A et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-7.
56. Waters V, Ratjen F. Inhaled liposomal amikacin. Expert Rev Respir Med 2014; 8: 401-9.
57. Cipolla D, Shekunov B, Blanchard J et al. Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv Drug Deliv Rev 2014; 75: 53-80.
58. Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008; 61: 859-68.
59. Bilton D, Pressler T, Falac I et al. Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (Arikacew) compared with TOBIw in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. In: Posters of the North American Cystic Fibrosis Conference, Salt Lake City, UT, 2013. Poster 235. Cystic Fibrosis Foundation, Bethesda, MD, USA.
60. Ehsan Z, Wetzel JD, Clancy JP. Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Expert Opin Investig Drugs 2014; 23: 743-9.
61. Moghaddam PH, Ramezani V, Esfandi E et al. Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol 2013; 239: 478-83.
62. Cheow WS, Chang MW, Hadinoto K. Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Pharm Res 2010; 27: 1597-609.
63. Cheow WS, Chang MW, Hadinoto K. Antibacterial efficacy of inhalable antibiotic-encapsulated biodegradable polymeric nanoparticles against E. coli biofilm cells. J Biomed Nanotechnol 2010; 6: 391-403.
64. Duan J, Vogt FG, Li X et al. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int J Nanomedicine 2013; 8: 3489-505.
65. Chono S, Suzuki H, Togami K et al. Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. Drug Dev Ind Pharm 2011; 37: 367-72.
66. Ong H, Traini D, Cipolla D et al. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res 2012; 29: 3335-46.
67. Ong HX, Benaouda F, Traini D et al. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. Eur J Pharm Biopharm 2014; 86: 83-9.
68. Yim D, Blanchard JD, Mudumba S et al. The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis. In: Dalby RN, Byron PR, Peart J et al., eds. Respiratory Drug Delivery. River Grove, IL: Davis Healthcare International, 2006; 425-8.
69. Sweeney LG,Wang Z, Loebenberg R et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005; 305: 180-5.
70. Finlay W, Lange C, Li Wet al. Validating deposition models in disease: what is needed? J Aerosol Med 2000; 13: 381-5.
71. Liu C, Shi J, Dai Q et al. In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. Drug Dev Ind Pharm 2015; 41: 272-8.
72. Alhariri M, Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother 2013; 57: 569-78.
73. Halder KK, Mandal B, Debnath MC et al. Chloramphenicol-incorporated poly lactide-co-glycolide (PLGA) nanoparticles: formulation, characterization, technetium-99m labeling and biodistribution studies. J Drug Target 2008; 16: 311-20.
74. Veloira WG, Domenico P, LiPuma JJ et al. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother 2003; 52: 915-9.
75. Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int J Pharm 2009; 365: 162-9.
76. Ungaro F, d'Angelo I, Coletta C et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012; 157: 149-59.
77. Rukholm G, Mugabe C, Azghani AO et al. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int J Antimicrob Agents 2006; 27: 247-52.
78. Ghaffari S, Varshosaz J, Saadat A et al. Stability and antimicrobial effect of amikacin loaded SLN. Int J Nanomedicine 2011; 6: 35-43.
79. Varshosaz J, Ghaffari S, Mirshojaei SF et al. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. Biomed Res Int 2013; 2013: 136859.
80. Pastor M, Moreno-Sastre M, Esquisabel A et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 2014; 477: 485-94.